Bio-Techne (NASDAQ: TECH) GC gets new RSU grants, no stock sales
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) reported that officer Shane Bohnen, SVP – General Counsel, received two equity awards on 2026-08-17: 11,344 Restricted Stock Units that vest in three annual installments from 2027–2029, and 18,432 Restricted Stock Units that vest on 2029-08-17. Each unit represents a contingent right to one share of common stock. Bohnen also reports direct holdings of 10,360 common shares and multiple outstanding stock options and performance RSUs with various exercise prices and vesting schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
15 transactions reported
Mixed
15 txns
Insider
Bohnen Shane
Role
SVP - General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F6, F11 | 11,344 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F6, F12 | 18,432 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F5 | -- | -- | -- |
| holding | Performance Restricted Stock Units F6, F7 | -- | -- | -- |
| holding | Performance Restricted Stock Units F6, F8 | -- | -- | -- |
| holding | Restricted Stock Units F6, F9 | -- | -- | -- |
| holding | Restricted Stock Units F6, F10 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 36,109 shares (Direct);
Stock Option (Right to Buy) — 68,334 shares (Direct);
Performance Restricted Stock Units — 24,004 shares (Direct);
Common Stock — 10,360 shares (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
- F3. Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
- F4. Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- F5. Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
- F6. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F9. 1,669 restricted stock units vest on 8/15/2027.
- F10. 2,332 restricted stock units vest on each of 8/15/2027 and 8/15/2028.
- F11. 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029.
- F12. 18,432 restricted stock units vest on 8/17/2029.
Key Figures
RSU grant 1: 11,344 units
RSU grant 2: 18,432 units
Direct common stock holdings: 10,360 shares
+4 more
7 metrics
RSU grant 1
11,344 units
Restricted Stock Units granted 2026-08-17, vesting 2027–2029
RSU grant 2
18,432 units
Restricted Stock Units granted 2026-08-17, vesting 2029-08-17
Direct common stock holdings
10,360 shares
Directly owned Bio-Techne common stock after reported transactions
Option exercise price
$66.97 per share
Stock option on 8,944 underlying common shares, expiring 2027-08-05
Longest-dated option
17,897 underlying shares
Stock option with $53.60 exercise price, expiring 2035-08-15
Performance RSUs 1
13,992 units
Performance Restricted Stock Units vesting based on goals by 2027
Performance RSUs 2
10,012 units
Performance Restricted Stock Units vesting based on goals by 2028
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Stock Option (Right to Buy), contingent right
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Vests in full or in part on 8/15/2027 if certain performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) underlying Bio-Techne common stock"
contingent right financial
"represents a contingent right to receive one share of Bio-Techne"
FAQ
What insider equity awards were reported at BIO-TECHNE Corp (TECH)?
BIO-TECHNE reported that SVP – General Counsel Shane Bohnen received two grants: 11,344 RSUs and 18,432 RSUs on 2026-08-17. The RSUs are compensation awards that convert into Bio-Techne common stock as they vest over future years.
When do Shane Bohnen’s new RSUs at BIO-TECHNE (TECH) vest?
The 11,344 RSUs vest in tranches of 3,781, 3,781 and 3,782 units in 2027–2029. The separate grant of 18,432 RSUs vests in full on 2029-08-17, subject to continued service and award terms.
What stock options does Shane Bohnen hold at BIO-TECHNE (TECH)?
Bohnen holds several stock options on Bio-Techne common stock, including tranches with exercise prices of $66.97, $74.91, $84.61, $94.52, $120.46, and $53.60. These options cover various underlying share amounts and expire between 2027 and 2035.
Does BIO-TECHNE’s Form 4 report any insider stock sales by Shane Bohnen?
No insider sales are reported; the filing shows only acquisitions of restricted stock units as compensation. The transaction summary lists 2 derivative acquisitions and no reported buys or sells of common stock on the transaction date.
What performance-based awards does Shane Bohnen hold at BIO-TECHNE (TECH)?
Bohnen holds performance restricted stock units covering 13,992 and 10,012 underlying shares of common stock. These PRSUs vest fully or partly in 2027 and 2028, depending on whether specified performance goals are achieved and certified.
AI-generated analysis. How Rhea-AI works. Not financial advice.
